Max (Matthew) Krummel is the Robert E. Smith and ImmunoX Inaugural Chair of Pathology at the University of California San Francisco. His lab specializes in the discovery and targeting of archetypal immune circuits, particularly those involving networks of cells coordinated around T cell-myeloid interaction, and their work spans scales from membrane organization and cell biology to the function of the whole immune system. His first work in science was the discovery and patenting of anti-CTLA-4, the first “checkpoint blockade” therapy for cancer, and subsequent translation has generated a collection of “myeloid tuning” approaches. His lab first isolated and characterized intratumoral CD103+ (cDC1) dendritic cells capable of stimulating T cells in tumor and their draining lymph nodes, and continues to map the cellular networks of both type I and type II DCs in tumors as well as other tissues, as a foundation for improving immune-based therapies.